STAGEZERO LIFE SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 CAD | -.--% |
|
-.--% | -11.11% |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 18.71 | 4.731 | 8.64 | 35.75 | 20.59 | 4.493 |
| Enterprise Value (EV) 1 | 20.25 | 7.849 | 11.03 | 32.72 | 20.22 | 6.277 |
| P/E ratio | -5.86 x | -1.14 x | -2.11 x | -3.84 x | -2.2 x | -0.39 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 45.4 x | 25.5 x | 62.3 x | 8.61 x | 4.06 x | 1.18 x |
| EV / Revenue | 49.2 x | 42.2 x | 79.5 x | 7.88 x | 3.99 x | 1.65 x |
| EV / EBITDA | -4.21 x | -1.93 x | -2.26 x | -10.6 x | -2.64 x | -0.84 x |
| EV / FCF | -6.47 x | -4.84 x | -3.46 x | -20.7 x | -6.31 x | -2.81 x |
| FCF Yield | -15.5% | -20.7% | -28.9% | -4.83% | -15.8% | -35.5% |
| Price to Book | -7.04 x | -1.05 x | -2.1 x | -29 x | 7.67 x | -0.62 x |
| Nbr of stocks (in thousands) | 13,084 | 17,949 | 31,198 | 60,717 | 88,233 | 101,533 |
| Reference price 2 | 1.430 | 0.2636 | 0.2769 | 0.5888 | 0.2333 | 0.0442 |
| Announcement Date | 4/2/18 | 4/3/19 | 5/20/20 | 4/1/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.4117 | 0.1859 | 0.1387 | 4.152 | 5.068 | 3.795 |
| EBITDA 1 | -4.81 | -4.057 | -4.881 | -3.1 | -7.652 | -7.507 |
| EBIT 1 | -5.158 | -4.367 | -5.14 | -3.355 | -7.963 | -7.747 |
| Operating Margin | -1,252.9% | -2,349.66% | -3,705.91% | -80.81% | -157.12% | -204.13% |
| Earnings before Tax (EBT) 1 | -2.947 | -3.944 | -3.482 | -6.864 | -7.484 | -11.42 |
| Net income 1 | -2.947 | -3.944 | -3.482 | -6.864 | -7.484 | -11.42 |
| Net margin | -715.96% | -2,121.82% | -2,510.24% | -165.32% | -147.67% | -300.79% |
| EPS 2 | -0.2440 | -0.2305 | -0.1314 | -0.1531 | -0.1058 | -0.1148 |
| Free Cash Flow 1 | -3.13 | -1.621 | -3.187 | -1.581 | -3.202 | -2.231 |
| FCF margin | -760.35% | -872.36% | -2,297.59% | -38.08% | -63.18% | -58.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/2/18 | 4/3/19 | 5/20/20 | 4/1/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.54 | 3.12 | 2.39 | - | - | 1.78 |
| Net Cash position 1 | - | - | - | 3.03 | 0.37 | - |
| Leverage (Debt/EBITDA) | -0.3207 x | -0.7687 x | -0.4893 x | - | - | -0.2377 x |
| Free Cash Flow 1 | -3.13 | -1.62 | -3.19 | -1.58 | -3.2 | -2.23 |
| ROE (net income / shareholders' equity) | 76.1% | 100% | 69.6% | 240% | -979% | 482% |
| ROA (Net income/ Total Assets) | -105% | -105% | -188% | -40% | -52% | -85.3% |
| Assets 1 | 2.805 | 3.742 | 1.848 | 17.14 | 14.4 | 13.38 |
| Book Value Per Share 2 | -0.2000 | -0.2500 | -0.1300 | -0.0200 | 0.0300 | -0.0700 |
| Cash Flow per Share 2 | 0 | 0.0100 | 0 | 0.1100 | 0.0200 | 0 |
| Capex | - | 0 | 0.04 | 0.07 | 0.15 | - |
| Capex / Sales | - | 1.5% | 31.99% | 1.74% | 2.92% | - |
| Announcement Date | 4/2/18 | 4/3/19 | 5/20/20 | 4/1/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -11.11% | 3.62M | |
| +0.17% | 42.86B | |
| +10.92% | 42.74B | |
| +44.30% | 41.36B | |
| -6.20% | 27.68B | |
| +5.23% | 25.15B | |
| -24.79% | 18.63B | |
| +26.69% | 12.37B | |
| -3.13% | 11.92B | |
| +6.57% | 11.21B |
- Stock Market
- Equities
- SZLS Stock
- Financials StageZero Life Sciences Ltd.
